ESTRO 38 Abstract book

S624 ESTRO 38

showed a significant difference at the end of hEBRT; Combination (M=12, SD=4.58) and Monotherapy (M=20.5, SD=9.97); p=0.041. EPIC-26 results are presented in Table 1.

require a face-to-face review could be identified. This serves as a proof of concept for the work of the digital technology team in our department and we are developing a pilot programme incorporating electronic PROM measures in RT review clinics to explore this in further detail. PO-1124 A pilot study: Utilization of PROMs in hypo- fractionated radiotherapy for localized prostate cancer K. Crowther 1 , P. Shiels 1 , A. Cole 1,2 , P. Shepherd 3 , S. Jain 1,2 , D. Mitchell 1 1 Belfast Health and Social Care Trust, Cancer Centre- Radiotherapy, Belfast, United Kingdom ; 2 Queen's University, Centre for Cancer Research and Cell Biology, Belfast, United Kingdom ; 3 Ulster University, School of Health Sciences, Belfast, United Kingdom Purpose or Objective Patient Reported Outcome Measures (PROMS) are a useful metric in evidence-based clinical care and translational research. Recording treatment toxicities and Quality of Life (QoL) scores can provide useful information in counseling future patients to aid decision-making and inform consent. Real time PROMS have the ability to improve patient care and guide changes to therapy. Curative treatment options for prostate cancer (PCa) include prostatectomy, brachytherapy, external beam radiotherapy (EBRT) and combination therapy utilizing EBRT followed by High Dose Rate Brachytherapy (HDR-BT). There is limited published evidence comparing PROMS for modern day radiotherapy techniques .This prospective study tested the feasibility of collecting multiple PROMS from PCa patients comparing HDR-BT combined with hypo- fractionated EBRT (hEBRT) (Combination Group) and hEBRT alone (Monotherapy Group). Material and Methods Between June and August 2017, 20 men with localised PCa with confirmed treatment regimen, consented to participate. Ten patients received combination therapy (37.5Gy/15f + 15Gy HDR implant) and ten received hEBRT (60Gy/20f). Urinary, bowel, sexual, hormone problems and QoL were examined before, during and after treatment, using validated PROMS questionnaire methods and analysed as specified by developers. The results presented using descriptive statistics including the Mann- Whitney U test to exam statistical significance. Results All participants completed treatment without interruption with 100% response rate to PROMs. SF-12 assessed QoL and results are summarized in Figure 1.

Final fraction of hEBRT bowel summary demonstrated a clinically relevant difference and statistically significant difference; Combination (M=85.42, SD=18.01) and Monotherapy (M=64.59, SD=25.89); p=0.03 this remained at Week 12 (p=0.005). Conclusion This small study showed excellent patient compliance with completion of PROMS. Both treatment groups tolerated treatment well and there was minimal impact on QoL. In relation to treatment-related symptoms, the monotherapy group reported a higher incidence of bowel toxicity compared to the combination group. The feasibility of collecting multiple PROMS is evidenced in this study, streamlining of these tools into integrated technology applications and real time PROMS measurement has the ability to benefit patients and guide clinicians in adapting therapies based on individual need. PO-1125 Helical Tomotherapy for patients with pectus excavatum treated for early stage breast cancer. A. Alexandre 1 , P. Dominique 1 , F. Alain 1 , K. Youlia M. 1 1 Institut Curie Ensemble Hospitalier, Radiothérapie, Paris cedex 05, France Purpose or Objective To evaluate our experience with Helical Tomotherapy (HT) for patients with pectus excavatum (PE) who received adjuvant radiotherapy (RT) for early stage breast cancer (BC). Material and Methods A retrospective study of all patients with PE treated by intensity modulated radiation therapy (IMRT) using HT between 2009 and 2015 was done. All patients received breast +/- boost or chest wall irradiation and most of them received lymph nodes (LN) irradiation. Dose constraints for organs at risk (OAR) were defined using optimization scale developed in our Department. Evaluation of early and late toxicity was done using Common Terminology Criteria for Adverse Events v.4.0 (CTCAE). Results Between 2009 and 2015, 179 patients were treated with adjuvant HT when conventional radiation therapy techniques cannot ensure an optimal dose distribution. Among them, 40 patients (7.8%) were presented with PE and were included in this study. Median age was 53 years (range 30-75). Twenty-nine patients (72.5%) received

International Index of Erectile Function (IIEF-5), International Prostate Symptom Score (IPSS) and Expanded Prostate Index Composite-26 (EPIC-26) assessed treatment-related symptoms. IIEF-5 demonstrated severe erectile dysfunction (ED) occurrence at baseline at 20% this increased to 80% at Week 12 within both groups. All men reported some ED symptoms at Week 12. IPSS results